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Abstract
Background: The CHL1 gene codes for a member of the L1 family of neural cell adhesion molecules. It is highly
expressed in the central and peripheral nervous system playing an important role in the building and functioning
on the brain. CHL1 proteins are also involved in axonal migration, synaptic formation and plasticity. In mice,
functional studies showed that the haploinsufficiency of Chl1 gene in the developing brain results in cognitive
deficits suggesting that the CHL1 gene at 3p26.3 is a candidate for an autosomal form of intellectual disability.
Furthermore, in humans deletions of CHL1 have been described in patients with neurodevelopmental delay
characterized by learning and language difficulties, seizures. Less is known about the potential effect of CHL1
overexpression, and microduplications of CHL1 have been rarely identified.
Case presentation: In this report, we describe a male patient with a phenotype characterized by developmental
delay, symptoms of hyperactivity, short attention span and speech delay. In addition, minor facial dysmorphic features
have been observed. Chromosomal microarray analysis revealed a rare de novo 0.85 Mb microduplication on the short
arm (p26.3) of chromosome 3, encompassing a single gene, CHL1. To the best of our knowledge, duplication of
chromosome 3p26.3, including only the CHL1 gene, has been described in only one intellectually disabled girl
with epilepsy. The duplication described here is the smallest reported so far. In addition, this is the first report
describing a patient in which the CHL1 duplication is a de novo event.
Conclusions: The clinical and molecular findings reported here are useful to provide further evidence that CHL1 is a
dosage sensitive gene suggesting that not only the deletion but also its duplication can cause non-syndromic
neurodevelopmental phenotypes.
Background
Cell adhesion molecules mediate various interactions
between cells and also between cells and the extracellu-
lar matrix in developing and mature brain. Thus, they
are intimately involved in the regulation of brain develop-
ment and function. The cell adhesion molecule L1-like
(CHL1) gene, located at the chromosomal sub-band
3p26.3, codes for a cell adhesion molecule of the immuno-
globulin superfamily due to the presence of six Ig-like
domains in its extracellular part. CHL1 is highly expressed
in neurons but is also detectable in astrocytes, oligo-
dendrocytes, and Schwann cells [1]. In the developing
brain, CHL1 regulates neurite outgrowth [1] and
neuronal migration [2], while in mature neurons it
accumulates in the axonal membrane and regulates
synapse function [3]. Deletions or mutations of CHL1
have been associated with learning and language diffi-
culties while Chl1+/− and Chl1−/− knockout mouse
models have provided evidence that Chl1 may contribute
to mental impairment associated with “3p-syndrome”
[4, 5]. Less is known about the clinical consequences
due to the reciprocal microduplications. Up to date,
only one patient, a female, carrier of a microduplication
in the CHL1 gene, inherited from her healthy father,
has been reported in literature [6]. The proband
showed significant ID, marked speech development
delay, generalized tonic-clonic seizures. Being the first
patient reported in literature carrier of a duplication
encompassing only the CHL1 gene, and since the dupli-
cation was inherited from a healthy parent, it remained
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unclear whether or not CHL1 was responsible for the
clinical phenotype observed. Here, we report another
patient with developmental delay (DD), symptoms of
hyperactivity, short attention span and speech delay
who has a de novo duplicated region, less than 1 mega-
base in size, encompassing only CHL1.
We review the clinical and molecular features of
CHL1 gene duplication cases discussing the function of




The patient is the first child of healthy, non-consanguineous
parents. He was born at term after a normal pregnancy
by cesarean section. Karyotype was normal male. His
younger brothers had normal development and school-
ing. No family history of congenital anomalies or DD/
ID was referred. Development was normal during the
neonatal period, no feeding problems were reported.
He managed to walk unsupported at the age of 1 year
showing, since the first year of life, language problems.
Medical Geneticist first clinically assessed the pa-
tient at 2 years and 3 months. His height was 96 cm
(90–97th centile), weight was 15 kg (75–90th centile)
and head circumference was 52 cm (50–75th centile).
Physical examination revealed minor dysmorphic facial
features consisting of mild hypertelorism, down-slanting
long palpebral fissures with eversion of lateral third of
lower eyelids, long philtrum, thin upper lip, mildly prom-
inent ear lobes (Fig. 1). Sleeping and feeding have been
considered normal, as well as brain MRI, EEG, ECG,
ocular and audiological assessment, abdomen echography,
carpal bone X-rays. Routine blood exams, aminoacidemia/
aminoaciduria, urinary organic acids’ panel and acyl-
carnitine blood spot were all in normal ranges.
Although the patient’s behavior was friendly and soci-
able, he showed symptoms of hyperactivity and his
attention span was short, but he was too young to con-
firm a diagnosis of attention deficit hyperactivity dis-
order (ADHD). Language development was delayed, and
he was able to say few words, incorrectly.
At his most recent clinical evaluation, at the age of
3 years and 3 months, the patient had difficulties to
focus and sustain his attention. In addition, he shoved
hyperactivity and severe speech delay. The family
stimulated spontaneous speech associated with few
unarticulated words. A neuropediatric examination
ruled out a neurological defect. Fragile X screening
was unremarkable.
Results
Chromosomal microarray analysis (CMA), performed by
high resolution SNP-array, showed an approximately
850 kb duplication on the short arm of chromosome 3 span-
ning 1,005 probes: arr[hg19]3p26.3(125,931–975,649)x3,
encompassing a single coding gene, CHL1. The adja-
cent probes of normal copy number are at position
125,742 distally, and 978,510 proximally, for a max-
imum duplication size of 852 kb. The duplication was
not found in the parents and was thus de novo (Fig. 2).
We carefully evaluated the microarray results and we
excluded the presence of other significant genomic im-
balance. The duplication was confirmed by an inde-
pendent array (data not showed).
Discussion
In this report, we present the first patient to date re-
ported with a de novo whole gene duplication of CHL1
in 3p26.3 chromosomal region. This is the only duplica-
tion encompassing CHL1 identified in our database of
over 3,000 individuals referred for copy number vari-
ation (CNV) analysis. In addition, duplications of CHL1
have not been reported in healthy individuals suggesting
a causative role for duplication of this gene in our
patient’s abnormal phenotype.
CHL1 encodes for a 1224-amino acid cell adhesion
protein that belongs to the immunoglobulin superfamily
due to the presence of six Ig-like domains in its extracel-
lular part. It is highly expressed in neurons but is also
detectable in astrocytes, oligodendrocytes, and Schwann
cells. Recent work suggests that CHL1 functions as a
regulator of synaptic chaperones and vesicle exocytosis.
Studies of Chl1-deficient mice have shown impaired sen-
sorimotor gating and neuronal connectivity [7, 8].
Fig. 1 Face of the proband at age of 2 years and 3 months showing
mild facial dysmorphic features listed in the text
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In humans, deletions affecting CHL1 underline a
spectrum of neurodevelopmental disorders. To date
four familial cases presenting deletions of chromo-
some 3p26.3 confined to CHL1 gene have been de-
scribed. Pohjola and collaborators [9] described a
patient showing mild learning problems, microcephaly
and growth retardation carrier of a CHL1 microdele-
tion inherited from his normal mother; later, a pair of
siblings has been reported with features including
microcephaly, learning difficulties, and ID who inher-
ited a deletion encompassing only the CHL1 gene
from their asymptomatic father [10]. More recently,
Tassano et al. [11] described a maternally inherited
0.95 Mb deletion on the 3p26.3, which removed only
the CHL1 gene, in a male with microcephaly, short
stature, mild ID, learning and language delay, and
strabismus.
Since the shared deleted region between the reported
cases encompassed only the CHL1 gene, and this latter
is highly expressed in the brain, the authors proposed
that although the deletion may have incomplete pene-
trance, the haploinsufficiency of the CHL1 gene could
be the main factor contributing to neurodevelopmental
delay observed in these patients.
Of note, a balanced translocation [46,Y,t(X;3)(p22.1;
p26.3)] with a breakpoint within intron five of the
CHL1 gene has previously been linked to ID, and an
animal model showed that Chl1+/− mice have a pheno-
type spectrum ranging from wild type to behavioral
abnormalities [5].
Taken together, these clinical, molecular and func-
tional data corroborate the hypothesis that CHL1 is the
candidate gene for the cognitive impairments in these
patients.
Less is known about the potential effect of CHL1 over-
expression, and microduplications of CHL1 have been
rarely identified.
Until now, only another patient carrier of a CNV
similar for size and chromosomal location to that iden-
tified in our patient, has been reported in medical
literature by Shoukier et al. [6]. The clinical manifesta-
tions of the present case along with the patient
reported by Shoukier et al. are listed in Table 1 while
the molecular data of the two patients are presented in
Fig. 3. A review of clinical features in these two patients
revealed overlapping phenotypes, namely, ID/DD and
speech delay. Since CHL1 has important regulatory
functions both in developing brain and in mature neu-
rons [1–3], we conclude that CHL1 duplication is likely
responsible for the patient’s phenotype. Our observa-
tion is also corroborated by the fact that the duplication
reported in the present case is the first described to
date as de novo event in a patient with non-syndromic
developmental delay. In addition, copy number varia-
tions of genes encoding for neural cell adhesion mole-
cules (NCAM), have been recently published in the
literature as responsible for neurodevelopmental disor-
ders further strengthening the hypothesis that chromo-
somal alteration affecting this family of genes can cause
neurodevelopmental disorders [12].
Fig. 2 Chromosome microarray analysis performed with the Affymetrix CytoScan HD array and visualized using the Affymetrix Chromosome
Analysis Suite version 3.0. Copy number state of each probe is drawn along chromosome 3 from 1 to 6.800.000 bp. The upper panel represents
the copy number state of the proband, the middle panel the mother and the lower panel the father. Values of Y-axis indicate the inferred copy
number according to probe intensities. Blue bar is the duplicated region identified in the patient
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Interestingly, epileptic seizures were reported in the
patient described by Shoukier et al. [6], whereas symp-
toms of hyperactivity and short attention span were
observed in our. Given the young age of ours patient,
we cannot exclude that he will manifest later signs of
epilepsy. In addition, since in one of the patients de-
scribed by Cuoco et al. [10], carrier of a CHL1 microde-
letion, seizure has been observed, we suggest a clinical
surveillance for this feature in the patients with CNVs
encompassing the CHL1 gene.
Finally, it is possible that the genes located in the
neighboring regions of the duplication have a role in the
etiology of the clinical phenotype reported in the patient.
In fact, chromosomal rearrangements frequently lead to
alteration of the genes’ environment and this may be
reflected in a change of expression, referred as a pos-
ition effect [13]. Of note, located at ~159 kb of the
centromeric breakpoint of the 3p26.3 duplication iden-
tified in the patient, there is contactin 6 (CNTN6) gene
(Fig. 2), which could be affected by the rearrangement
and related to the phenotype. CNTN6 is a neuronal
membrane protein acting as a cell adhesion molecule
involved in the formation of axon connection in the
developing nervous system. As well as for other mem-
bers of this protein family, CNTN6 has been suggested
as a disease-causing gene in neurodevelopmental disor-
ders [14]. In mice, CNTN6 participates in embryonic
development and postnatal brain maturation and its defi-
ciency causes profound motor coordination abnormalities
and learning difficulties [15]. In humans, microdeletions
and microduplications of CNTN6 have been reported in
patients with DD, ID, speech and language delays, atypical
autism suggesting that under- and overexpression of this
gene is responsible for the observed phenotypes [16]. In
Fig. 3 Snapshot of the 3p26.3 region displayed using the UCSC Genome browser [GRCh37/hg19 assembly; http://genome.ucsc.edu] showing the
CHL1 duplications seen in the present patient and in the first patient reported in the literature
Table 1 Summary of the clinical features and molecular data of the reported patients with 3p26.3 microduplication encompassing
only the CHL1 gene
Features Present case Shoukier et al. [6]
Dup. size 0.85 Mb 1.0 Mb
Coordinates (hg19) 125,931–975,649 48,914–1,054,209
Inheritance de novo maternal
Sex and age at diagnosis M, 2.3 years F, 16 years
Weight 15 Kg (75–90th centile) 57 Kg (50th centile)
Height 96 cm (90–97th centile) 157 cm (25th centile)
Head circumference 52 cm (50–75th centile) 53.4 cm (25th centile)
DD/ID + +
Language delay + +
Seizure - +
Hyperactivity/attention deficit + -
Dysmorphisms + -
Delivery at term at term
Age at walking 12 months 15 months
Age at first words 20 months 24 months
Dup duplication, M male, F female, + present, − absent, DD developmental delay, ID intellectual disability, NR not reported
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agreement with Shoukier et al. [6], we cannot exclude
the existence of a position effect on the CNTN6 gene,
as already reported for others copy number variations
[17, 18]. Obviously, this observation need to be eluci-
dated by further gene expression studies either on
experimental in vivo animal models or on diagnostic
material.
Conclusions
In conclusion, to our knowledge this is the first reported
case of an isolated de novo CHL1 duplication in a patient
with a non-syndromic clinical phenotype characterized
by developmental and speech delays, hyperactivity and
short attention span. Our data are useful to better
understand the role that the duplicated gene play in the
clinical outcome, corroborating the hypothesis that not
only the deletion but also the duplication of CHL1 is
associated with non-syndromic forms of DD/ID.
Materials and methods
Snp array analysis
We extracted DNA from the lymphocytes of patient and
his parents using BioRobot EZ1 (Qiagen, Solna, Sweden).
Genomic screening for copy number variations (CNVs)
was carried out using the CytoScan HD array platform
(Affymetrix, Santa Clara, CA) as previously described [19].
The array contains more than 2,600,000 CNV markers
across the genome, including 750,000 genotype-able single
nucleotide polymorphism (SNP) markers. Data analysis
were performed using the Chromosome Analysis Suite
Software version 3.0: (1) the raw data file (CEL) was nor-
malized using the default options; (2) an unpaired analysis
was performed using as baseline 270 HapMap samples in
order to obtain Copy numbers value from. CEL files while
the amplified and/or deleted regions were detected using
a standard Hidden Markov Model (HMM) method. A
copy number variation was validated if an abnormal log2
ratio was obtained for at least 25 contiguous probes. DNA
sequence information refer to the public UCSC database
hg19 assembly (Build GRCh37, February 2009) while mo-
lecular karyotype was designated according to ISCN 2013.
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